ParenteralDosed ingredient
Cosmetic cross-reference
Glycerin
CAS 56-81-5
Glycerin (CAS 56-81-5) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 940 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
3
SOURCE
DrugCentral / FAERS
Adverse signals
940
SOURCE
IUPHAR / PharmGKB
PubMed IDs
0
SOURCE
ChEMBL 36
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Glycerin
CAS Number
56-81-5
UNII
PDC6A3C0OX
InChIKey
PEDCQBHIVMGVHV-UHFFFAOYSA-N
ChEMBL ID
CHEMBL692
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural productparenteral
SOURCE
ChEMBL 36
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL692 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
ChEMBL 36 activities + assays
3 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 30000 nM | 31 | - |
| - | Potency | 21969.157142857144 nM | 7 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
SOURCE
DrugCentral 2023 / FAERS disproportionality
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Macular degeneration | 341 | 1092.361 | 10025409 |
| Creatinine renal clearance decreased | 133 | 343.255 | 10011372 |
| Sedation complication | 125 | 340.178 | 10079741 |
| Blood calcium decreased | 139 | 287.183 | 10005395 |
| Constipation | 313 | 242.16 | 10010774 |
| Chronic sinusitis | 92 | 227.65 | 10009137 |
| Orthostatic hypotension | 141 | 223.255 | 10031127 |
| Sedation | 133 | 206.145 | 10039897 |
| Procedural pain | 99 | 205.226 | 10064882 |
| Paraesthesia oral | 95 | 202.172 | 10057372 |
| Cognitive disorder | 138 | 178.619 | 10057668 |
| Depressed level of consciousness | 149 | 178.508 | 10012373 |
| Balance disorder | 145 | 147.828 | 10049848 |
| Mobility decreased | 142 | 115.981 | 10048334 |
| Vaginal flatulence | 35 | 105.79 | 10064227 |
| Female genital tract fistula | 36 | 82.511 | 10061149 |
| Dyspepsia | 110 | 76.722 | 10013946 |
| Proctitis | 35 | 75.904 | 10036774 |
| Vaginal discharge | 35 | 72.924 | 10046901 |
| Radiculopathy | 37 | 71.242 | 10037779 |
| Ocular procedural complication | 16 | 62.707 | 10080964 |
| Multiple drug therapy | 25 | 61.649 | 10074950 |
| Eye irritation | 41 | 48.07 | 10015946 |
| Therapeutic product effect incomplete | 103 | 46.771 | 10082200 |
| Pain | 315 | 46.257 | 10033371 |
| Fall | 219 | 45.948 | 10016173 |
| Frequent bowel movements | 44 | 45.931 | 10017367 |
| Drug ineffective | 450 | 43.446 | 10013709 |
| Superinfection | 20 | 42.412 | 10042566 |
| Keratitis | 20 | 41.544 | 10023332 |
| Hypotension | 186 | 39.718 | 10021097 |
| Abdominal pain | 176 | 39.165 | 10000081 |
| Mouth swelling | 21 | 39.102 | 10075203 |
| Oral candidiasis | 39 | 38.452 | 10030963 |
| Contraindicated product administered | 3 | 37.115 | 10078504 |
| Colitis ulcerative | 42 | 36.091 | 10009900 |
| Joint swelling | 15 | 34.639 | 10023232 |
| Completed suicide | 3 | 32.481 | 10010144 |
| Pustule | 13 | 31.091 | 10037578 |
| Weight decreased | 165 | 30.914 | 10047895 |
| Volvulus | 14 | 29.316 | 10047697 |
| Erythema | 109 | 28.693 | 10015150 |
| Pyrexia | 246 | 28.619 | 10037660 |
| Synovitis | 3 | 28.43 | 10042868 |
| Therapeutic product effect decreased | 5 | 28.073 | 10082201 |
| Peripheral swelling | 14 | 27.825 | 10048959 |
| False positive investigation result | 10 | 27.253 | 10070748 |
| Arthropathy | 9 | 26.263 | 10003285 |
| Haematochezia | 57 | 26.114 | 10018836 |
| Intestinal obstruction | 40 | 25.965 | 10022687 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
RxNorm drug names
4 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Glycerin | 4910 | SU | MTHSPL |
| GLYCERIN | 4910 | SU | MTHSPL |
| glycerin | 4910 | SU | MTHSPL |
| glycerin | 4910 | IN | RXNORM |
SOURCE
SIDER side-effect resource
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | glycerol | LLT | C0232487 |
| Abdominal discomfort | glycerol | PT | C0232487 |
| Abdominal pain | glycerol | LLT | C0000737 |
| Abdominal pain | glycerol | PT | C0000737 |
| Abdominal pain upper | glycerol | LLT | C0232492 |
| Abdominal pain upper | glycerol | PT | C0232492 |
| Ammonia increased | glycerol | LLT | C0541772 |
| Ammonia increased | glycerol | PT | C0541772 |
| Anaphylactic shock | glycerol | LLT | C0002792 |
| Anaphylactic shock | glycerol | PT | C0002792 |
| Angioedema | glycerol | LLT | C0002994 |
| Angioedema | glycerol | PT | C0002994 |
| Asthenia | glycerol | PT | C0004093 |
| Asthma | glycerol | LLT | C0004096 |
| Asthma | glycerol | PT | C0004096 |
| Bradycardia | glycerol | LLT | C0428977 |
| Bradycardia | glycerol | PT | C0428977 |
| Conjunctivitis | glycerol | LLT | C0009763 |
| Conjunctivitis | glycerol | PT | C0009763 |
| Cough | glycerol | LLT | C0010200 |
| Cough | glycerol | PT | C0010200 |
| Cyanosis | glycerol | LLT | C0010520 |
| Cyanosis | glycerol | PT | C0010520 |
| Decreased appetite | glycerol | LLT | C0232462 |
| Decreased appetite | glycerol | PT | C0232462 |
| Dermatitis | glycerol | PT | C0011603 |
| Diarrhoea | glycerol | LLT | C0011991 |
| Diarrhoea | glycerol | PT | C0011991 |
| Dizziness | glycerol | PT | C0012833 |
| Dizziness | glycerol | LLT | C0012833 |
| Dizziness | glycerol | PT | C0012833 |
| Dyspepsia | glycerol | LLT | C0013395 |
| Dyspepsia | glycerol | PT | C0013395 |
| Dyspnoea | glycerol | LLT | C0013404 |
| Dyspnoea | glycerol | PT | C0013404 |
| Erythema | glycerol | LLT | C0041834 |
| Erythema | glycerol | PT | C0041834 |
| Fatigue | glycerol | LLT | C0015672 |
| Fatigue | glycerol | PT | C0015672 |
| Flatulence | glycerol | LLT | C0016204 |
| Flatulence | glycerol | PT | C0016204 |
| Flushing | glycerol | LLT | C0016382 |
| Flushing | glycerol | PT | C0016382 |
| Gastrointestinal disorder | glycerol | LLT | C0017178 |
| Gastrointestinal disorder | glycerol | PT | C0017178 |
| Gastrointestinal pain | glycerol | PT | C0687713 |
| Headache | glycerol | LLT | C0018681 |
| Headache | glycerol | PT | C0018681 |
| Hyperammonaemia | glycerol | LLT | C0220994 |
| Hyperammonaemia | glycerol | PT | C0220994 |
| Hypotension | glycerol | LLT | C0020649 |
| Hypotension | glycerol | PT | C0020649 |
| Lacrimation | glycerol | LLT | C0423153 |
| Lacrimation increased | glycerol | PT | C0152227 |
| Local reaction | glycerol | LLT | C0853813 |
| Local reaction | glycerol | PT | C0853813 |
| Loss of consciousness | glycerol | PT | C0041657 |
| Malnutrition | glycerol | LLT | C0162429 |
| Malnutrition | glycerol | PT | C0162429 |
| Nausea | glycerol | LLT | C0027497 |
| Nausea | glycerol | PT | C0027497 |
| Nervous system disorder | glycerol | LLT | C0027765 |
| Nervous system disorder | glycerol | PT | C0027765 |
| Oedema peripheral | glycerol | LLT | C0085649 |
| Oedema peripheral | glycerol | PT | C0085649 |
| Pain | glycerol | LLT | C0030193 |
| Pain | glycerol | PT | C0030193 |
| Pallor | glycerol | LLT | C0030232 |
| Pallor | glycerol | PT | C0030232 |
| Pruritus | glycerol | LLT | C0033774 |
| Pruritus | glycerol | PT | C0033774 |
| Rash | glycerol | LLT | C0015230 |
| Rash | glycerol | PT | C0015230 |
| Rhinitis | glycerol | LLT | C0035455 |
| Rhinitis | glycerol | PT | C0035455 |
| Shock | glycerol | PT | C0036974 |
| Sneezing | glycerol | LLT | C0037383 |
| Sneezing | glycerol | PT | C0037383 |
| Swelling | glycerol | LLT | C0038999 |
| Swelling | glycerol | PT | C0038999 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Glycerin used for in pharmaceutical contexts?
Glycerin (CAS 56-81-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Glycerin?
Glycerin has 940 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Creatinine renal clearance decreased, Sedation complication, Blood calcium decreased, Constipation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Glycerin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glycerin with EU status "permitted".
What clinical phase is Glycerin in?
Glycerin is rendered with ChEMBL max phase 4 (approved).